Latest news
Loading news…
TaiMed Biologics
ActiveOperating status — whether the company still runs independently. “Closed” usually means it was acquired, merged, or shut down.🔥 MediumHeat score — how much recent activity & attention the company has (web traffic, news, hiring).📈 High growthGrowth score — momentum trend across web traffic, headcount and other growth signals. Taipei, T'ai-pei, Taiwan Founded 2007 51-100 employees For Profit
TaiMed Biologics is a biotechnology company that develops monoclonal antibody therapeutics for HIV disease.
Total Funding
Available in Pro Last Funding
Available in Pro Acquisitions
0
Monthly Visits
Available in Pro Contacts
8
Patents
4
6 trademarks
Company Details
Funding & Financials
Pro- Total funding
- Funding rounds
- Last funding
- Last funding type
- Last funding date
- Funding status
- Total equity funding
- Revenue range
IPO & Stock
- IPO status
- Private
Web Traffic
Pro- Monthly visits
- Global traffic rank
- 6-mo avg visits
- Visit duration (s)
- Pages / visit
- Bounce rate
- Rank change (mo)
Technology & IP
- Active technologies
- 25
- Patents granted
- 4
- Trademarks
- 6
- Top patent class
- Medical Or Veterinary Science; Hygiene
Company Info
- Founded
- 2007
- Employees
- 51-100
- Operating status
- Active
- Company type
- For Profit
- Org types
- company
- Founders
- 3
- News articles
- 14
- HQ
- Taipei, T'ai-pei, Taiwan
- Region
- Asia-Pacific (APAC)
Signals & Scores
- Heat score
- Medium
- Growth score
- High
- Trend (7d)
- -0.2
- Trend (30d)
- 2.4
- Trend (90d)
- 3.1
Key People at TaiMed Biologics
Scientific Founder
Chief Technology Officer
Chief Financial Officer
CEO
Co-Founder
Co-Founder
8
professional contacts at TaiMed Biologics
Contact execs at TaiMed Biologics →Explore 200,000+ acquisitions — free
Filter the full database across sectors, companies, dates, and deal sizes. No signup, no paywall.
Recent News related to TaiMed Biologics
Loading news…
FAQs about TaiMed Biologics
People who checked this page also checked these
Browse the full Acquirezy directory.